MedVital Raises INR 18 Cr Led by Alkemi Growth Capital for Wound Care Expansion

The company said the capital will be used to expand operations, accelerate product development, and build proprietary capabilities across devices, biomaterials, and biologics.

MedVital, a medtech company focused on skin repair and regeneration, has raised Rs 18 crore in a growth funding round led by Alkemi Growth Capital, with participation from Dr Sanjay Arora, Shubhan Ventures, and existing investors. The round follows its earlier funding led by 4point0 Health Ventures and entrepreneur investors.

The company said the capital will be used to expand operations, accelerate product development, and build proprietary capabilities across devices, biomaterials, and biologics. It will also focus on improving supply chain efficiency and unit economics.

Founded in 2024, MedVital operates at the intersection of advanced wound care, regenerative aesthetics, and chronic dermatological conditions. The company is targeting gaps in clinical treatment linked to wound healing, ageing, and long-term skin conditions by developing evidence-based medical technologies tailored for specific use cases.

Its advanced wound care segment includes the NoWound portfolio, featuring Negative Pressure Wound Therapy (NPWT) systems and a chitosan-based liquid bandage designed for hospital use. The company noted that adoption of advanced wound care therapies in India remains at an early stage despite significant demand. MedVital reports early traction with deployments across more than 200 corporate and public healthcare institutions, supported by repeat usage.

In parallel, the company has introduced Elyara, a regenerative medical aesthetics portfolio focused on non-invasive skin and hair restoration. The products are based on peptide-led signaling and regenerative pathways.

Commenting on the development, Dr Varun Gupta, co-founder, MedVital, said, “Skin, the body’s largest organ, is increasingly impacted by ageing, diabetes and chronic dermatological conditions, yet access to innovative, evidence-based technologies remains limited. We are building clinically driven technologies across wound care, aesthetics, and dermatology.”

Alka Goel, founder and managing partner, Alkemi Growth Capital, said the company is addressing a growing clinical need through a platform-led approach, supported by early hospital adoption and product depth.

Dr Sanjay Arora, founding partner, Shubhan Ventures, highlighted the company’s focus on product quality, regulatory readiness, and long-term capability building.

MedVital plans to expand its presence across hospitals and healthcare institutions while continuing investments in clinical education and adoption of evidence-based treatments.

Stay tuned for more such updates on Digital Health News